Genomic profiling can be useful in pancreatic cancer, but it more valuable for research than it is for daily practice, explains Sahai. Data suggest that 27% of patients with metastatic pancreatic cancer may actually have a targetable mutation; however, only 3% of these patients are paired with a therapeutic option. Watch here . . .